These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24923845)

  • 21. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
    Kennedy GA; Morris KL; Subramonpillai E; Curley C; Butler J; Durrant S
    Br J Haematol; 2013 Jun; 161(6):794-801. PubMed ID: 23590671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
    Yacobovich J; Stark P; Barzilai-Birenbaum S; Krause I; Pazgal I; Yaniv I; Tamary H
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):564-7. PubMed ID: 20733517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy.
    Vill K; Müller-Felber W; Teusch V; Blaschek A; Gerstl L; Huetker S; Albert MH
    Neuromuscul Disord; 2016; 26(4-5):322-5. PubMed ID: 27068298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?
    Vlachaki E; Chatzinikolaou K; Bekiari E; Klonizakis F; Tsapas A
    Angiology; 2011 May; 62(4):346-8. PubMed ID: 21306999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olfactory dysfunction in β-thalassemia major patients treated with iron-chelating agents.
    Derin S; Erdogan S; Sahan M; Azik MF; Derin H; Topal Y; Topal H
    Ear Nose Throat J; 2017; 96(10-11):E8-E12. PubMed ID: 29121379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
    Panigrahi I; Vaidya PC; Bansal D; Marwaha RK
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):51-3. PubMed ID: 22215098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deferasirox in thalassemia patients with end-stage renal disease.
    Beydoun HG; Saliba AN; Taher AT
    Am J Hematol; 2016 Oct; 91(10):E456-7. PubMed ID: 27342388
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
    Voskaridou E; Plata E; Douskou M; Papadakis M; Delaki EE; Christoulas D; Terpos E
    Br J Haematol; 2010 Jan; 148(2):332-4. PubMed ID: 19863539
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient.
    Ricchi P; Costantini S; Spasiano A; Di Matola T; Cinque P; Prossomariti L
    Acta Haematol; 2011; 125(4):222-4. PubMed ID: 21273766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient.
    Anastasi S; Lisi R; Abbate G; Caruso V; Giovannini M; De Sanctis V
    Pediatr Endocrinol Rev; 2011 Mar; 8 Suppl 2():345-7. PubMed ID: 21705992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major.
    Yesilipek MA; Karasu G; Kazik M; Uygun V; Ozturk Z
    Pediatr Hematol Oncol; 2010 Aug; 27(5):374-9. PubMed ID: 20604682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferasirox induced liver injury in haemochromatosis.
    Imran FS; Phatak P
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):718; author reply 718. PubMed ID: 22078360
    [No Abstract]   [Full Text] [Related]  

  • 40. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.
    Marano M; Bottaro G; Goffredo B; Stoppa F; Pisani M; Marinaro AM; Deodato F; Dionisi-Vici C; Clementi E; Falvella FS
    Eur J Clin Pharmacol; 2016 Feb; 72(2):247-8. PubMed ID: 26403473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.